Table 5.

Summary of ALK-positive, crizotinib-refractory cases

Resistant casesALK fusionALK amplificationALK secondary mutationEGFR mutationKRAS mutation
3429/29 (100%)3/29 (10.3%)7/34 (20.6%)0/25 (0%)0/25 (0%)